Skip Navigation



NDT Advance Access published online on November 26, 2007
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfm801
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
23/1/17    most recent
gfm801v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ketteler, M.
Right arrow Articles by Biggar, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ketteler, M.
Right arrow Articles by Biggar, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org


After Several Years of Witchhunting: Can Calcium-Based Phosphate Binding be Released on Probation?

Markus Ketteler and Patrick Biggar

Department of Nephrology, Klinikum Coburg, Coburg, Germany

Correspondence and offprint requests to: Prof. Markus Ketteler, III. Medizinische Klinik (Nephrologie), Klinikum Coburg, Ketschendorfer Str. 33, 96450 Coburg, Germany. Tel: +49-9561-249611; Fax: +49-9561-249612; E-mail: markus.ketteler@klinikum-coburg.de

Keywords: atherosclerosis; calcification; calcium; phosphate; sevelamer

The first 10% of the full text of this article appears below.



   Introduction
 
The experimental model of uraemic ApoE-deficient mice has become increasingly used to investigate treatment options in the setting of chronic renal failure (CRF) created by 5/6-nephrectomy or other surgical methods, in combination with severe atherosclerotic plaque disease. Although the pathologic changes associated with this model are not immediately comparable to the development of CRF and atherosclerosis in humans, the phenotypic features of both vascular damage and biochemical abnormalities appear quite similar to what is observed in patients with progressive chronic kidney disease (CKD).

Phosphate binders and experimental atherosclerosis
In 2005, Phan et al. first published a study demonstrating that the phosphate binder sevelamer ameliorated not only vascular calcification, but also plaque progression in uraemic ApoE-deficient mice [1]. In addition to effective phosphate . . . [Full Text of this Article]

Calcium-based phosphate binding: effective and an innocent bystander?
From bench to bedside: the good and the bad news
Support from clinical studies: calcium and calcification progression in pre-dialysis patients
What do we learn?

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?